Astellas is aiming to create an “industry leading” gene therapy company with the $3 billion acquisition of San Fran biotech, Audentes Therapeutics.
The acquisition sees Astellas add a fifth ‘Primary Focus in Genetic Regulation’ to its ‘Astellas Focus Area’ approach. Under this focus, gene therapy will be a key driver of the company’s future growth, it said.
“Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM),” said Kenji Yasukawa, President and CEO of Astellas.
“By joining together with Audentes’ talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases.”
The deal is expected to be completed in Q1 2020.